38.6c New Delhi, India, Monday, February 02, 2026
Top Stories Supreme Court
Political NEWS Legislative Corner Celebstreet International Videos
Subscribe Contact Us
close
Executive

Govt. Bans Saridon And 327 Other Drugs Due To Health Risk.

By LawStreet News Network      13 September, 2018 12:00 AM      0 Comments
Govt. Bans Saridon And 327 Other Drugs Due To Health Risk.

The Ministry of Health on September 12, 2018, banned the manufacture for sale or distribution of 328 fixed-dose combination (FDC) drugs with immediate effect. The banned medicines include brands like Piramals Saridon, Alkem Laboratories Taxim AZ and Macleods Pharmas Panderm Plus cream.

Besides, banning 328 FDCs the ministry has also restricted the manufacture, sale or distribution of six FDCs subject to certain conditions, an official statement said.

Government sources said the move means that around 6,000 medicine brands belonging to different companies and with a combined market size of Rs. 2,000-2,500 crore may soon vanish from the drug market in the country. FDCs are two or more drugs combined in a fixed ratio into a single dosage form.

Earlier, on March 10, 2016, the Health Ministry, through a notification had prohibited the manufacture for sale and distribution for human use of 349 FDCs under Section 26 A of the Drugs and Cosmetics Act, 1940.

However, the matter was contested by the drug manufacturers in various high courts and the Supreme Court. The apex court on December 15, 2017, asked for the matter to be examined by an expert panel formed by the Drugs Technical Advisory Board (DTAB). The Board in its report to the Centre stated that there is no therapeutic justification for the ingredients contained in 328 FDCs and that these FDCs may involve risk to human beings.

Further, DTAB said these combinations may lead to overuse. According to the technical body, there is no need to expose the patients to that many ingredients when one will do the work. The notification stated, Hence in the larger public interest, it is necessary to prohibit the manufacture, sale or distribution of this FDCany kind of regulation or restriction to allow for any use in patients is not justifiable.

The Board recommended that it is necessary to prohibit the manufacture, sale or distribution of these FDCs under the Drugs and Cosmetics Act, 1940 in the larger public interest.

 



Share this article:

User Avatar
About:


Leave a feedback about this
TRENDING NEWS


TOP STORIES

vande-mataram-at-150-constitutional-reverence-judicial-restraint-and-the-limits-of-legal-nationalism
Trending Know The Law
Vande Mataram at 150: Constitutional Reverence, Judicial Restraint, and the Limits of Legal Nationalism

At 150, Vande Mataram’s constitutional status, judicial restraint, and the limits of legal nationalism reveal India’s unresolved debate on law and reverence.

28 January, 2026 12:19 PM
delhi-hc-upholds-family-pension-for-remarried-childless-widow-of-crpf-personnel-parents-not-entitled
Trending Judiciary
Delhi HC Upholds Family Pension for Remarried Childless Widow of CRPF Personnel; Parents Not Entitled [Read Judgment]

Delhi High Court rules that a remarried childless widow of a CRPF personnel remains entitled to family pension; dependent parents have no claim under Rule 54.

28 January, 2026 03:56 PM
iran-warns-of-unprecedented-retaliation-amid-renewed-us-threats-over-nuclear-program
Trending International
Iran Warns of Unprecedented Retaliation Amid Renewed U.S. Threats Over Nuclear Program

Iran warns of unprecedented retaliation as U.S. threats over its nuclear program intensify, raising legal, diplomatic, and geopolitical concerns.

29 January, 2026 11:51 AM
india-eu-free-trade-agreement-provokes-us-rebuke-over-russian-oil-ties
Trending International
India–EU Free Trade Agreement Provokes U.S. Rebuke Over Russian Oil Ties

India and the EU seal a historic FTA, drawing sharp U.S. criticism over Russian oil ties, tariffs, and shifting global trade and geopolitical alignments.

29 January, 2026 12:07 PM

ADVERTISEMENT


Join Group

Signup for Our Newsletter

Get Exclusive access to members only content by email